Administration of a tumor necrosis factor inhibitor at the time of myocardial infarction attenuates subsequent ventricular remodeling

被引:49
作者
Berry, MF
Woo, YJ
Pirolli, TJ
Bish, LT
Moise, MA
Burdick, JW
Morine, KJ
Jayasankar, V
Gardner, TJ
Sweeney, HL
机构
[1] Univ Penn, Sch Med, Div Cardiothorac Surg, Dept Surg, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA
关键词
D O I
10.1016/j.healun.2004.06.021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Tumor necrosis factor (TNF) causes myocardial extracellular matrix remodeling and fibrosis in myocardial infarction and chronic heart failure models. Pre-clinical and clinical trials of TNF inhibition in chronic heart failure have shown conflicting results. This study examined the effects of the administration of a TNF inhibitor immediately after myocardial infarction on the development of heart failure. Methods: Lewis rats underwent coronary artery ligation and then received either intravenous etanercept (n = 14), a soluble dimerized TNF receptor that inhibits TNF, or saline as control (n = 13). Leukocyte infiltration into the infarct borderzone was evaluated 4 days post-ligation in 7 animals (etanercept = 4, control = 3). After 6 weeks, the following parameters were evaluated in the remaining animals: cardiac function with a pressure-volume conductance catheter, left ventricular (LV) geometry, and borderzone collagenase activity. Results: Etanercept rats had significantly less borderzone leukocyte infiltration 4 days post-infarction than controls (10.7 +/- 0.5 vs 18.0, +/-2.0 cells/high power field; p<0.05). At 6 weeks, TNF inhibition resulted in significantly reduced borderzone collagenase activity (110 +/- 30 vs 470 140 activity units; p<0.05) and increased LV wall thickness (2.1 +/- 0.1 vs 1.8 +/- 0.1 mm, p<0.05). Etanercept rats had better systolic function as measured by maximum LV pressure (84 +/- 3 mm Hg vs 68 +/- 5 mm Hg, p<0.05) and the maximum change in left ventricular pressure over time (maximum dP/dt) (3,110 +/- 230 vs 2,260 +/- 190 mm Hg/sec, p<0.05), and better diastolic function as measured by minimum dP/dt (-3,060 +/- 240 vs -1,860 +/- 230 mm Hg/sec; p<0.05) and the relaxation time constant (14.6 +/- 0.6 vs 17.9 +/- 1.2 msec; p<0.05). Conclusions: TNF inhibition after infarction reduced leukocyte infiltration and extracellular matrix turnover and preserved cardiac function.
引用
收藏
页码:1061 / 1068
页数:8
相关论文
共 38 条
[1]   Increased mRNA expression of tumour necrosis factor-α and its converting enzyme in circulating leucocytes of patients with acute myocardial infarction [J].
Akatsu, T ;
Nakamura, M ;
Satoh, M ;
Hiramori, K .
CLINICAL SCIENCE, 2003, 105 (01) :39-44
[2]  
*AM HEART ASS, 2003, HEART DIS STROK STAT
[3]  
Anzai T, 1997, CIRCULATION, V96, P778
[4]   Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction [J].
Askari, AT ;
Brennan, ML ;
Zhou, XR ;
Drinko, J ;
Morehead, A ;
Thomas, JD ;
Topol, EJ ;
Hazen, SL ;
Penn, MS .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (05) :615-624
[5]   Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure [J].
Bozkurt, B ;
Torre-Amione, G ;
Warren, MS ;
Whitmore, J ;
Soran, OZ ;
Feldman, AM ;
Mann, DL .
CIRCULATION, 2001, 103 (08) :1044-1047
[6]   Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats [J].
Bozkurt, B ;
Kribbs, SB ;
Clubb, FJ ;
Michael, LH ;
Didenko, VV ;
Hornsby, PJ ;
Seta, Y ;
Oral, H ;
Spinale, FG ;
Mann, DL .
CIRCULATION, 1998, 97 (14) :1382-1391
[7]   Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-α [J].
Bryant, D ;
Becker, L ;
Richardson, J ;
Shelton, J ;
Franco, F ;
Peshock, R ;
Thompson, M ;
Giroir, B .
CIRCULATION, 1998, 97 (14) :1375-1381
[8]   Blocking the development of postischemic cardiomyopathy with viral gene transfer of the apoptosis repressor with caspase recruitment domain [J].
Chatterjee, S ;
Bish, LT ;
Jayasankar, V ;
Stewart, AS ;
Woo, YJ ;
Crow, MT ;
Gardner, TJ ;
Sweeney, HL .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2003, 125 (06) :1461-1469
[9]   Increased systolic performance with diastolic dysfunction in adult spontaneously hypertensive rats [J].
Cingolani, OH ;
Yang, XP ;
Cavasin, MA ;
Carretero, OA .
HYPERTENSION, 2003, 41 (02) :249-254
[10]   Safety and efficacy of a soluble P75 tumor necrosis factor receptor (enbrel, etanercept) in patients with advanced heart failure [J].
Deswal, A ;
Bozkurt, B ;
Seta, Y ;
Parilti-Eiswirth, S ;
Hayes, FA ;
Blosch, C ;
Mann, DL .
CIRCULATION, 1999, 99 (25) :3224-3226